Blog
RSS FeedPosted by Michael Wonder on 20 Feb 2023
TGA grants provisional approval to Moderna’s COVID-19 bivalent (Spikevax Bivalent Original/Omicron BA.4-5) booster dose vaccine
20 February 2023 - On 17 February, 2023, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine: elasomeran and ...
Posted by Michael Wonder on 19 Feb 2023
Health Canada authorises Moderna's Omicron targeting bivalent COVID-19 vaccine in children & adolescents (6-17 years)
17 February 2023 - The recommendation is based on clinical data for Moderna's bivalent Omicron targeting COVID-19 vaccine, mRNA.1273.214. ...
Posted by Michael Wonder on 16 Feb 2023
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines
16 February 2023 - NICE has today issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 ...
Posted by Michael Wonder on 16 Feb 2023
Moderna says its COVID vaccine will remain free for all consumers, even those uninsured
16 February 2023 - Moderna was criticised for considering a price hike for its shot. ...
Posted by Michael Wonder on 09 Feb 2023
COVID-19 vaccine safety report (09 February 2023)
9 February 2023 - To 5 February 2023, over 44 million doses of Comirnaty have been administered in Australia, as well ...
Posted by Michael Wonder on 08 Feb 2023
All adults now eligible for a 2023 COVID-19 booster dose
8 February 2023 - The Australian Government has accepted advice from the Australian Technical Advisory Group on Immunisation that all adults ...
Posted by Michael Wonder on 08 Feb 2023
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine
8 February 2023 - On 20 January 2023, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.4/5 vaccine for use ...
Posted by Michael Wonder on 08 Feb 2023
ATAGI 2023 booster advice
8 February 2023 - Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) regarding COVID-19 boosters in 2023. ...
Posted by Michael Wonder on 01 Feb 2023
Simcere’s COVID-19 pill goes on sale in China at less than half the price of Pfizer’s Paxlovid
31 January 2023 - The retail price of Simcere Pharmaceutical’s orally taken COVID-19 treatment, which was only approved to go ...
Posted by Michael Wonder on 30 Jan 2023
Junshi Biosciences announces approval for marketing of VV116 in China
30 January 2023 - Shanghai Junshi Biosciences announced today that the NMPA has conducted urgent review and approval under special examination ...
Posted by Michael Wonder on 29 Jan 2023
COVID-19 vaccine safety report (27 January 2023)
27 January 2023 - Since the beginning of the vaccine rollout to 22 January 2023, almost 65 million doses of COVID-19 ...
Posted by Michael Wonder on 27 Jan 2023
Valeo Pharma announces filing of a new drug submission with Health Canada for sabizabulin for the treatment of hospitalised COVID-19 patients
26 January 2023 - In the final analysis of the Phase 3 clinical study conducted by Veru, sabizabulin showed a 51.6% ...
Posted by Michael Wonder on 26 Jan 2023
Update on US FDA emergency use authorisation of Evusheld
26 January 2023 - The US FDA has stated that AstraZeneca’s Evusheld (tixagevimab and cilgavimab) is not currently authorised for ...
Posted by Michael Wonder on 23 Jan 2023
TGA grants provisional approval to Pfizer’s COVID-19 bivalent (Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine
23 January 2023 - On 20 January 2023, the TGA granted provisional approval to Pfizer’s bivalent COVID-19 vaccine: tozinameran and famtozinameran ...
Posted by Michael Wonder on 13 Jan 2023
COVID-19 vaccine safety report (12 January 2023)
12 January 2023 - Since the beginning of the vaccine rollout to 8 January 2023, almost 65 million doses of COVID-19 ...